What is Eagle Pharmaceuticals, Inc.'s annual revenue?

Eagle Pharmaceuticals, Inc. (EGRX) reported annual revenue of $317.0M in its most recent fiscal year.

What is Eagle Pharmaceuticals, Inc.'s net profit?

Eagle Pharmaceuticals, Inc. (EGRX) reported net profit of $36.0M in its most recent fiscal year.

What is EGRX EV/EBITDA?

Eagle Pharmaceuticals, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 0.22.

OTC · Financial Statements

Eagle Pharmaceuticals, Inc. (EGRX) Financial Statements

$0.37 OTC: EGRX Market Cap $4.87M

Eagle Pharmaceuticals, Inc. most recently reported annual revenue of $317.0M, net profit of $36.0M, revenue has compounded at 6.0% a year over the last five years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Annual Financials (USD)

Metric	2019	2020	2021	2022	2023
Revenue	$196.0M	$188.0M	$172.0M	$317.0M	—
Operating Profit	$22.0M	$33.0M	$3.0M	$81.0M	—
Net Profit	$14.0M	$12.0M	$-9.0M	$36.0M	—
EPS	$1.01	$0.87	$-0.66	$2.73	—
Op Margin	11.1%	17.6%	1.6%	25.6%	—

Balance Sheet (USD)

Metric	2019	2020	2021	2022	2023
Total Assets	$255.0M	$253.0M	$254.0M	$406.0M	—
Total Liabilities	$75.0M	$67.0M	$77.0M	$173.0M	—
Cash	$110.0M	$103.0M	$98.0M	$55.0M	—
Borrowings	$39.0M	$38.0M	$30.0M	$68.0M	$0

Cash Flow (USD)

Metric	2019	2020	2021	2022	2023
Operating Cash Flow	$56.0M	$49.0M	$28.0M	$51.0M	$31.0M
Investing Cash Flow	$-2.0M	$-19.0M	$-6.0M	$-87.0M	$0
Financing Cash Flow	$-18.0M	$-33.0M	$-20.0M	$-19.0M	$0
Net Cash Flow	$31.0M	$-7.0M	$-5.0M	$-42.0M	$31.0M
Free Cash Flow	$55.0M	$49.0M	$28.0M	$51.0M	$31.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.22
FCF Yield	632.60%
Quick Ratio	1.27
Interest Coverage	20.01
Return 1Y	-89.97%
Return 3Y	-98.01%
Return 5Y	-99.21%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

EGRX Overview EGRX Dividend Run Stock Screener